This company has been acquired
DMT Stock Overview
Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
Small Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.15 |
| 52 Week High | CA$0.21 |
| 52 Week Low | CA$0.06 |
| Beta | 0.86 |
| 1 Month Change | -11.76% |
| 3 Month Change | 114.29% |
| 1 Year Change | -9.09% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -83.33% |
Recent News & Updates
Shareholder Returns
| DMT | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | -6.3% | -5.2% | -0.002% |
| 1Y | -9.1% | -48.5% | 17.3% |
Return vs Industry: DMT exceeded the Canadian Pharmaceuticals industry which returned -32.9% over the past year.
Return vs Market: DMT underperformed the Canadian Market which returned -0.8% over the past year.
Price Volatility
| DMT volatility | |
|---|---|
| DMT Average Weekly Movement | 20.3% |
| Pharmaceuticals Industry Average Movement | 12.2% |
| Market Average Movement | 8.5% |
| 10% most volatile stocks in CA Market | 18.3% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: DMT's share price has been volatile over the past 3 months.
Volatility Over Time: DMT's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | George Tziras | www.smallpharma.com |
Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company’s product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
Small Pharma Inc. Fundamentals Summary
| DMT fundamental statistics | |
|---|---|
| Market cap | CA$50.37m |
| Earnings (TTM) | -CA$19.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs DMT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMT income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$19.31m |
| Earnings | -CA$19.31m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DMT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/10/26 07:36 |
| End of Day Share Price | 2023/10/20 00:00 |
| Earnings | 2023/08/31 |
| Annual Earnings | 2023/02/28 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Small Pharma Inc. is covered by 5 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tania Armstrong-Whitworth | Canaccord Genuity |
| Elemer Piros | D. Boral Capital LLC. |
| Sepehr Manochehry | Eight Capital |